Pfizer: Urinary Bladder, Overactive trials

The registry lists 35 Urinary Bladder, Overactive studies with Pfizer as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 1 6Phase 2 5Phase 3 11Phase 4 7No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Drug Use Investigation for ToviazCompletedNCT01936870Results posted
• A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of FesoterodineCompletedNCT01302067Phase 4Results posted
• A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.CompletedNCT01302054Phase 4Results posted
• This Is A Study Of Bioavailability And Food Effect For Fesoterodine.CompletedNCT01286454Phase 1Results posted
• Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz TherapyTerminatedNCT01091519Results posted
• Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive BladderCompletedNCT01054222Phase 4Results posted
• This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive BladderCompletedNCT00943735Results posted
• A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive BladderCompletedNCT00928070Phase 4Results posted
• A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary UrgencyCompletedNCT00911937Phase 4Results posted
• Toviaz Post Marketing Surveillance StudyCompletedNCT00879398Results posted
• Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 YearsCompletedNCT00857896Phase 2Results posted
• UK Study Assessing Flexible Dose Fesoterodine in AdultsCompletedNCT00806494Phase 4Results posted
• A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.CompletedNCT00798434Phase 4Results posted
• Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).CompletedNCT00795509Results posted
• Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous TherapyCompletedNCT00691093Results posted
• Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.CompletedNCT00658684Phase 3Results posted
• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.CompletedNCT00611026Phase 3Results posted
• Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.CompletedNCT00561951Phase 2Results posted
• Fesoterodine "add-on" Male Overactive Bladder StudyCompletedNCT00546637Phase 3Results posted
• Fesoterodine Flexible Dose StudyCompletedNCT00536484Phase 3Results posted
• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)CompletedNCT00444925Phase 3Results posted
• A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder PatientsCompletedNCT00425100Phase 3Results posted
• A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy VolunteersCompletedNCT01566760Phase 1
• The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsCompletedNCT00914667Phase 1
• A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy SubjectsCompletedNCT00902681Phase 1
• A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy SubjectsCompletedNCT00902187Phase 1
• A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031CompletedNCT00814736Phase 1
• Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive BladderCompletedNCT00746681Phase 2
• A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic MonitoringCompletedNCT00646880Phase 3
• Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive BladderCompletedNCT00479505Phase 2
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder SyndromeCompletedNCT00220402Phase 3
• Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension PhaseCompletedNCT00220389Phase 2
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder SyndromeCompletedNCT00220376Phase 3
• A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder SyndromeCompletedNCT00220363Phase 3
• Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder SyndromeCompletedNCT00138723Phase 3